Lanhao Biotech Secures Nearly Tens of Millions RMB in Pre-A Funding to Advance Oral Regenerative and Aesthetic Medicine Products

VCBeat has learned that Qingdao BlueHao Biotechnology Co., Ltd. (“BlueHao Bio”) completed a Pre-A financing round of nearly RMB 10 million several months ago. The round was jointly invested by a pharmaceutical industry fund and Chongyi Capital. The funds will be primarily used for animal studies, clinical trials, and product registration.

Lanhao Bio was established in August 2019. Its founder and CEO, Chen Defu, holds a master’s degree from Peking University Health Science Center and holds a senior professional title in biomedical materials.With over 20 years of experience in the research and development of products for human tissue regeneration and repair,Possesses extensive expertise in product development, clinical trials, regulatory registration applications, and the management of innovative product projects.

Chen Defu has held senior executive positions at several well-known biomaterials companies in China. The products he was responsible for and involved in developing,Secured over 20 Class III medical device registration certificates, with cumulative use in more than 2 million patient cases.In particular, in the field of bone repair materials, Chen Defu has engaged in “industry-academia-research-application” collaborations with renowned domestic hospitals and research institutions, including Beijing Jishuitan Hospital, Peking Union Medical College Hospital, the Academy of Military Medical Sciences, the Chinese PLA General Hospital, and West China Hospital of Sichuan University.

The domestic dental and medical aesthetics sectors are booming, with major investment firms actively positioning themselves in the downstream clinical service segment. However, they have overlooked high-end dental medical devices and consumables, as well as raw materials for medical aesthetics, resulting in long-term import monopolies in the upstream device and consumable markets.

In fact, upstream devices and consumables determine whether downstream sectors can achieve healthy and sustainable development. Against the backdrop of the pandemic, upstream medical devices have emerged as the next major growth opportunity in the dental and medical aesthetics industries. Therefore, Lan Hao Biotechnology has chosen to position itself atDevelopment of Upstream Oral Regenerative and Restorative Materials and Medical Aesthetic Products, such as oral bone powder and collagen repair materials.

Among them, oral bone powder, also known as "dental implant bone powder," is primarily used for repairing alveolar bone defects and increasing bone volume during dental implant procedures. This product is manufactured from bovine bone through complex pretreatment and calcination processes. Lan Hao Biotechnology'sFeatured Dental Bone Graft Project, adoptedMore effective pretreatment methods and more refined calcination processes,Lower raw material and production costs,Performance rivals that of top-tier international products, with the potential to gradually achieve import substitution. Relevant technologies have been filed for national invention patents, and one software copyright has been obtained.

Collagen-based repair materials include collagen dressings and collagen hemostatic sponges. The company has independently developedAdvanced Collagen Extraction and Modification Technologies, with mature technology and low cost, it is suitable for large-scale and industrialized development. The company’s collagen raw materials include various grades such as cosmetic-grade, medical-grade, implantable-grade, and injectable-grade. Tested by medical device testing centers accredited by the National Medical Products Administration (NMPA), all indicators exceed industry standards, among whichThe purity of Type I collagen exceeds 99.80%, significantly higher than the industry standard requirement of 96%.

Over the past two years since its establishment, Lan Hao Bio has achieved rapid growth in its start-up phase, leveraging its profound technological expertise, extensive industrialization experience, and exceptional project execution capabilities. Currently, Lan Hao Bio has completedDevelopment of 5 Class III medical device products and 2 Class II medical device productsAll products have been tested at testing centers designated by the National Medical Products Administration (NMPA). It is expected that within the next two years, Lan Hao Biotech will obtain registration certificates for multiple Class III and Class II medical devices, enabling rapid market entry. With the support of our partners’ robust marketing networks, we aim to achieve anticipated economic and social benefits, laying a solid foundation for the company’s future initial public offering (IPO).

As is well known, the fields of oral health and medical aesthetics have witnessed rapid development in recent years, attracting increasing attention from investment institutions. In 2020, the market size of dental medical devices reached approximately RMB 26.2 billion, with dental implants and orthodontic products accounting for about 70% of the total market. By 2025, the market size of dental medical devices is expected to reach RMB 50 billion, surpassing that of orthopedic devices, which warrants significant attention.

Chen Defu stated, “At present, high-end dental products such as dental implants, bone graft materials, prosthodontic materials, and endodontic treatment materials are still predominantly imported devices, leaving substantial room for growth for domestically produced alternatives. Early investment in relevant Chinese dental device companies is poised to yield significant returns in the long run.”